You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205111 - 205120 of 207712 results
  1. Innovative Optical System for Hemagglutination Assays

    SBC: INDEVR, INC            Topic: NIAID

    PROJECT SUMMARY The Hemagglutination assay HA and Hemagglutination Inhibition HI assay are widely used methods for characterizing viruses bacteria and antibodies The World Health Organization recently recommended that HI remain the gold standard method for influenza seroepidemiology Although the HA and HI assays are applied worldwide they have the disadvantages of manual plate reading no ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Drugs Targeting Dormant Tumors as Anti-Metastatic Agents

    SBC: DORMATARG, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Most patients with solid tumors die of tumor recurrence at the same site or metastasis of the tumor to distal sites. An intermediate step in both recurrence and metastasis is a stage called tumor dormancy, where the cancer cells are suppressed by a normal extracellular matrix (ECM) and by other mechanisms. Such cells can appear histopathologically normal and th ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Therapeutic phage host-range prediction using proximity-guided metagenomics and artificial intelligence

    SBC: PHASE GENOMICS, INC.            Topic: NIAID

    ABSTRACT There is growing interest in the therapeutic application of phage for treatments of antibiotic-resistant infections and gut microbiome-related disorders. Phage therapies have the advantage of potentially extreme specificity for their targets leading to very little in the way of off-target side effects when compared with traditional antibiotic therapy. However, the identification of phage ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  4. High Performance, Electrically-Assisted Ionic Monopropellant Thruster

    SBC: PHYSICAL SCIENCES INC.            Topic: N161067

    Physical Sciences Inc. proposes to develop a unique ionic monopropellant thruster for next generation DACS that uses an electrically-assisted ignition technique to generate rapid thrust impulses with short ignition delay times. The thruster will produce these short delay times with low power consumption using a novel monopropellant decomposition strategy and a high performance electrode arrangemen ...

    SBIR Phase II 2017 Department of DefenseNavy
  5. High channel count electrophysiology and data processing for freely-moving animals

    SBC: Leaflabs, LLC            Topic: 101

    PROJECT SUMMARY Simultaneous recording and stimulation of larger populations of neurons distributed throughout the brain is needed to rigorously evaluate theories of neural computation at the cellular level in mammalsPreviouslywe introduced close packed silicon probesScholvin et aland a direct to disk data acquisition architectureKinney et alto enablechannel neural recording in head fixed animalsP ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Small Molecule Inhibitors of HIV Nef Virulence Factor for Treatment of HIV AIDS


    DESCRIPTION provided by applicant While HIV AIDS can be managed with antiretroviral drugs these agents do not clear the virus and require life long administration Recently we discovered a completely new class of compounds that interfere with the HIV virulence factor called Nef This viral protein is critical to HIV replication in vivo immune escape of HIV infected cells and AIDS progre ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimers Disease

    SBC: PRECYTE INC            Topic: NIA

    DESCRIPTION provided by applicant We are developing the Indicator Cell Assay Platform iCAP a broadly applicable and inexpensive platform for blood based diagnostics that can be used for early detection of disease and as a companion diagnostic for drug development The iCAP uses cultured cells as biosensors capitalizing on the ability of cells to respond differently to signals present in th ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Measureable Residual Disease testing for acute myeloid leukemia with single-cell genotyping

    SBC: MISSION BIO INC            Topic: 102

    Abstract Relapse is the primary obstacle to cure in acute and chronic leukemia. The detection of measurable residual disease (MRD) is a direct measure of disease burden, treatment efficacy and is the strongest predictor of relapse. Although MRD has been established as a standard of care procedure and as a measurement of outcomes in clinical trials for chronic myeloid (CML) and acute lymphoblastic ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Improved Oral P selectin Blocker for Prophylactic Sickle Cell Disease Therapy


    Abstract Sickle cell disease SCD is a poorly treated inherited debilitating condition for which Vanguard Therapeutics Inc is developing a promising new long term oral therapy A dire need exists for our drug as the millions of SCD patients worldwide and in the US continue to suffer with episodic pain episodes disability and premature death Current treatments have well defined lim ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health

    SBC: INIMMUNE CORP            Topic: 82

    There are very few FDA approved adjuvants available, limiting the discovery and development of vaccines to combat new pathogens that threaten public health. Inimmune Corp has developed a fully synthetic TLR4 agonist, INI-2002, with superior potency and stability versus other licensed TLR4 adjuvants. Simultaneously, Adjuvance Technologies has developed TQL-1055, a semi-synthetic and less toxic form ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government